Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a significant unmet medical need, with encouraging early clinical trial results indicating a 42% improvement in fibrosis compared to a 24% placebo response. The company is strategically positioned within a growing market, leveraging its partnerships with AbbVie and BI to enhance revenue and research capabilities while exploring complementary roles in therapies that target metabolic and cardiovascular benefits for patients with type 2 diabetes. Given the positive clinical developments and a reinforced outlook on the product's potential efficacy and market penetration, Inventiva's growth prospects appear robust within the biopharmaceutical sector.

Bears say

Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for treating non-alcoholic steatohepatitis (NASH), a condition without approved therapies, yet it faces significant challenges that could negatively impact its share performance. The company reported a substantial net loss of €175.9 million, raising concerns about its financial stability and ability to fund its operations amid ongoing development risks associated with its key clinical program, which could face efficacy or safety issues. Furthermore, the reliance on research partnerships for revenue, the potential for clinical trial setbacks, and competition from other therapies compound the risks surrounding Inventiva's growth trajectory, suggesting a precarious future outlook.

Inventiva S.A. (IVA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.